Autopsy report · NCT00493454
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
Cause of deathSlow enrollment
“Slow accrual.”
Life of this trial
- Registered 1 year 2 months after it had already started.
- Ran for about 4 years 11 months before it stopped.
- 6 participants enrolled.
- Results were posted on the registry 2 years 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Lymphoma
- Interventions
- Zevalin; Rituximab; ^111 In Ibritumomab Tiuxetan
- Participants
- 6
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.